Background {#Sec1}
==========

Herbert's model {#Sec2}
---------------

In his Herman Award Lecture of 1986, Victor Herbert proposed his *Sequential stages in the development of vitamin B*~12~*deficiency* (Herbert [@CR47]). Herbert's hypothesis, describing the *Biochemical and hematological sequence of events as negative vitamin B*~12~*balance progresses*, two decades later formed the basis for the introduction of the commercial holotranscobalamin (HoloTC, Active B12) immunoassay for the diagnosis of vitamin B~12~ deficiency.

The concentration of total vitamin B~12~ in serum is not a sufficiently sensitive or specific indicator for the reliable diagnosis of vitamin B~12~ deficiency (Herbert [@CR47], [@CR48]; Hølleland et al. [@CR57]; Snow [@CR99]; Oh and Brown [@CR87]; Solomon [@CR101]; Herrmann and Obeid [@CR50], [@CR51]; Schrempf et al. [@CR94]; Heil et al. [@CR46]). Herbert observed that, as with iron and folate, the range of normal concentrations of serum total vitamin B~12~ for an individual is narrower than the range of normal for a population (Herbert [@CR47]): "the laboratory test result becomes abnormal for the individual before it exceeds the range of normal for the laboratory". As observed by Snow "As knowledge has accumulated, the limitations of such tests as serum vitamin levels ... have become apparent".

The two metabolites of vitamin B~12~, homocysteine (tHcy) and methylmalonic acid (MMA) have been proposed as more sensitive than total serum vitamin B~12~, for the diagnosis of vitamin B~12~ deficiency (Hølleland et al. [@CR57]; Snow [@CR99]; Oh and Brown [@CR87]). In support of the use of these metabolites Oh and Brown say that "use of a low serum vitamin B~12~ level as the sole means of diagnosis may miss up to one half of patients with actual tissue B~12~ deficiency". In advocating the use of methylmalonic acid, Hølleland et al. state that "Our data emphasize the poor diagnostic utility of low and low-normal s-cobalamin assay results and call for more sensitive and specific markers of cobalamin deficiency. s-MMA meets these criteria". Solomon ([@CR101]) differed, finding that methylmalonic acid and homocysteine were also unreliable for the diagnosis of vitamin B~12~ deficiency.

Even now, after decades of research, there is still no agreed *gold*-*standard* test for vitamin B~12~ deficiency. As recently stated by Aparicio-Ugarriza et al. ([@CR5]): "There is no consensus in the literature about cut-off points for blood vitamin B~12~ reference ranges and its associated metabolites." It is against the background of this unmet need that the holotranscobalamin (HoloTC, Active B12) immunoassay has been offered as a solution.

Holotranscobalamin (HoloTC) is cobalamin (vitamin B~12~) attached to the transport protein transcobalamin (TC), in the serum, for delivery to cells for metabolism. The absorption and transport of vitamin B~12~ is described in detail in Neale ([@CR79]). Recent developments in understanding the role of HoloTC in the assimilation and metabolism of vitamin B~12~ are explained in detail by Quadros ([@CR90]). Fedosov ([@CR36], [@CR37]) has produced a mathematical model for the biochemical markers of vitamin B~12~ deficiency, including HoloTC.

Herbert proposed serum holotranscobalamin (HoloTC) as an earlier and more sensitive indicator of vitamin B~12~ deficiency than total vitamin B~12~ (Herbert [@CR47], [@CR48]). According to Herbert ([@CR48]): "Low concentrations of holoTCII occur before low concentrations of total serum vitamin B-12 or before deficiency". This is based on two properties of HoloTC; the small percentage of total vitamin B~12~ existing as HoloTC, and the short half-life of HoloTC. According to Herbert ([@CR48]), HoloTC comprises only 20 % of serum total vitamin B~12~; this metabolically active portion is carried to all cells on the transport protein transcobalamin (TC). The remaining 80 % (holohaptocorrin, HoloHC) is the metabolically inert component carried on the liver storage protein haptocorrin (HC). According to Herbert ([@CR48]), HoloTC has a short half-life of only 6 min compared to 240 h for HoloHC. There is disagreement about the actual half-life of HoloTC, as discussed later in this review, but the consensus is that it is far shorter than that of HoloHC.

According to Herbert's 1986 model (Herbert [@CR47]), vitamin B~12~ deficiency develops in a sequence of four distinct stages, with changes in specific biochemical and haematological markers defining the borders between them (Fig. [1](#Fig1){ref-type="fig"}; Table [1](#Tab1){ref-type="table"}). The earliest sign of vitamin B~12~ deficiency is marked by the change from *Normal* to *Negative B*~12~*Balance*, with HoloTC concentration falling from \>22 to \<15 pmol/L, and TC saturation falling from \>5 to \<5 %. Haematology is normal for the first two stages; initial abnormal haematology, in the form of neutrophil hypersegmentation, appears in stage 3; overtly abnormal haematology in the form of neutrophil hypersegmentation, macroovalocytes, elevated MCV and low haemoglobin, appears in stage 4. MMA is possibly increased in stage three and definitely increased in stage four.Fig. 1Herbert's 1986 model for sequential stages in the development of vitamin B~12~ deficiency. This simplified model was derived from Herbert ([@CR47])Table 1Herbert's hypothesis---differences between 1986 and 1994 modelsAnalyteModelDeficiency stage12341986NormalNegative B~12~ balanceB~12~ depletionB~12~-deficient erythropoiesisB~12~-deficiency anaemia1994NormalEarly negative B~12~ balanceB~12~ depletionDamaged metabolism: B~12~-deficient erythropoiesisClinical damage: B~12~-deficiency anemiaHoloTC (pmol/L)1986\>22\<15\<15\<9\<9HoloTC (pmol/L)1994\>37\<30\<30\<30\<30TC saturation (%)1986\>5\<5\<2\<1\<1TC saturation (%)1994\>5\<4\<4\<4\<4HoloHC (pmol/L)1986\>111\>111\<111\<74\<74HoloHC (pmol/L)1994\>133\>133\<111\<74\<74MMA high1986NoNoNo?YesMMA high1994NoNoNo?YestHcy high1986----------tHcy high1994NoNoNoYesYesData in this table was derived from Herbert ([@CR47], [@CR48])HoloTC concentration converted from pg/mL to pmol/L, using formula from Herbert ([@CR47]): HoloTC (pmol/L) = HoloTC (pg/mL) × 0.74Two stages preceding "Normal", added by Herbert in the 1994 model, omitted from this table

From his 1986 model, Herbert concluded that "By measuring holo TC II one can diagnose negative vitamin B-12 balance, a stage which precedes the stage of B-l2 depletion", and thus proposed HoloTC to be more sensitive than total serum vitamin B~12~ as an indicator of the onset of vitamin B~12~ deficiency. Herzlich and Herbert ([@CR56]) stated: "The data suggest low holo TC II indicates negative B~12~ balance early in the development of tissue depletion of B~12~ ... We believe that this parameter provides a new tool for assessing nutritional status in equivocal states". Wickramasinghe and Fida ([@CR107]) supported Herbert's hypothesis, concluding that "Our data support the model of developing B~12~ deficiency proposed by Herbert and his colleagues and their view that a proper study of B~12~ values should include not only measurements of total serum B~12~ but also of holoTCII concentration". Neale ([@CR79]) more cautiously commented on the hypothesis: "A reduction in the circulating concentration of holo-TCII may be the earliest sign of vitamin B~12~ deficiency. This potentially important observation awaits confirmation".

Herbert modified his model in 1990 and again in 1994 (Herbert [@CR48]), adding two *Positive Balance* stages before the *Normal* stage, and changing the HoloTC and TC thresholds (Fig. [2](#Fig2){ref-type="fig"}; Table [1](#Tab1){ref-type="table"}). Homocysteine, the second metabolite of vitamin B~12~, is included in this revised model. These changes broaden the range of analytes considered while reducing the relative differences in analyte concentrations, particularly HoloTC concentration and TC saturation, between stages. The range of HoloTC concentration thresholds has been reduced significantly, with the difference between normal and deficient conditions much less clear.Fig. 2Herbert's ([@CR48]) model for sequential stages in the development of vitamin B~12~ deficiency. This simplified model was derived from Herbert ([@CR48])

The most important effect of the reduction in the range of HoloTC concentration thresholds is in the diagnosis of the very earliest progression from normality to deficiency; the detection of *Negative vitamin B*~12~*Balance* (Table [1](#Tab1){ref-type="table"}). In Herbert's original 1986 model, HoloTC concentration needs to fall from \>22 to \<15 pmol/L, to progress from *Normal* to *Negative Vitamin B*~12~*Balance*, a fall of 33 %. In the revised model of 1994, HoloTC concentration needs to fall from \>37 to \<30 pmol/L, to progress from *Normal* to *Early Negative Vitamin B*~12~*Balance*, a fall of 20 %. Because of the smaller percentage fall in HoloTC required to change from normal to abnormal in the revised model, despite the absolute value of the differences between these stages remaining the same, the diagnosis of *Negative Vitamin B*~12~*Balance* now requires greater precision and accuracy in the individual assay and greater certainty of the HoloTC cut-off levels.

Commercialisation of the HoloTC immunoassay {#Sec3}
-------------------------------------------

Commercialisation of the HoloTC test commenced when the company Axis-Shield of Norway, and the University of Aarhus in Denmark, participated in a joint venture: Project E! 2263---HOLOTC "Development Of Diagnostic Test For Holotc", from April 2000 to February 2005 (Eureka [@CR34]). The stated objective of the project was to develop a new test that is simple and reliable for the diagnosis of vitamin B~12~ deficiency. Nexo et al. ([@CR82]), from the University of Aarhus, reported a new method for measurement of HoloTC. Ulleland et al. ([@CR102]), sponsored by Axis-Shield, reported having developed the first reliable assay for HoloTC.

The HoloTC test as an alternative to the total vitamin B~12~ assay was further supported, from October 2002 to March 2006, by the European Union demonstration project: QLK3-CT-2002-01775 "Demonstration of the clinical utility of holotc as an early marker of vitamin b~12~ deficiency" (European Union [@CR35]). The project was coordinated by the University of Aarhus in Denmark; other participants were Axis-Shield and the University of Bergen in Norway, the University of Oxford in the UK and Trinity College Dublin in Ireland. The stated aims of the project were to: "demonstrate the analytical performance of this assay in 4 countries; to show its superiority to conventional methods for assessment of vitamin B~12~ status; and to demonstrate its value in older patients with depression or dementia".

As the commercial partner in the development of the HoloTC immunoassay, Axis-Shield has published several documents in support of the HoloTC test as an alternative to the total vitamin B~12~ assay (Axis-Shield [@CR7], [@CR8], [@CR9], [@CR10], [@CR11]). In their presentation of February 2007, Axis-Shield cites Herbert's model for the sequential development of vitamin B~12~ deficiency. A modified version of Herbert's ([@CR48]) hypothesis, as a simplified diagram, was provided to support the claim that HoloTC is a more sensitive indicator of vitamin B~12~ deficiency than is total vitamin B~12~. The same diagram was used by Ralph Green in his detailed presentation to the *Specialty Labs Web Conference* of December 2007, when supporting the case for using HoloTC for the diagnosis of vitamin B~12~ deficiency (Green [@CR43]).

Based on Herbert's models, in which the HoloTC concentration falls as the vitamin B~12~ status progresses from *Normal* to *Negative Vitamin B*~12~*Balance* as the first evidence of deficiency, Axis-Shield ([@CR7]) claims that "Active-B12 levels react early in the process" and "Active-B12 levels are low in patients with biochemical signs of vitamin B~12~ deficiency".

Axis-Shield ([@CR7]) cites Herrmann et al. ([@CR52]), saying "Data suggests improved identification of B~12~ deficient patients with Active-B12 compared to total serum B~12~".

Axis-Shield initially marketed their own immunoassay kit for HoloTC, then formed partnerships with manufacturers of automated immunoassay analysers. In 2006 Axis-Shield marketed their RIA (radioimmunoassay) kit for HoloTC (Axis-Shield [@CR8]), the first commercially available test for holotranscobalamin. In 2007 Abbott Laboratories, in partnership with Axis-Shield, commenced marketing their MEIA (Microparticle Enzyme Immunoassay) for assay of HoloTC on the AxSYM analyser (Abbott Laboratories [@CR1]; Axis-Shield and Abbott Laboratories [@CR12], [@CR13], [@CR14], [@CR15]; Brady et al. [@CR01], [@CR21]). Pry ([@CR89]), for Abbott Laboratories, presented *Holo Transcobalamin; A Predictor of Vitamin B*~12~*Status*. Brady et al. ([@CR21]), employees of Axis-Shield, stated that "The AxSYM Active B12 assay allows rapid, precise, sensitive, specific, and automated measurement of human holoTC in serum and plasma". In 2011 Abbott Laboratories broadened the application for the HoloTC kit to include their automated Architect high-throughput immunoassay analyser (Abbott Laboratories [@CR2]). IBL International ([@CR64]) markets an enzyme-immunoassay (ELISA) kit, and Siemens is currently developing a HoloTC kit for use on their ADVIA Centaur immunoassay system.

Review {#Sec4}
======

Summary of original research and previous reviews {#Sec5}
-------------------------------------------------

Results from previous original research, for HoloTC sensitivity and specificity compared to total vitamin B~12~, are summarised in Table [2](#Tab2){ref-type="table"}. Many authors concluded that HoloTC is an earlier and more sensitive indicator of the onset of vitamin B~12~ deficiency than total vitamin B~12~ (Table [3](#Tab3){ref-type="table"}, column 1). Other original studies have concluded that there is no significant improvement in sensitivity of HoloTC in comparison to total vitamin B~12~ (Table [3](#Tab3){ref-type="table"}, column 2). Quotations from original reports are available in tables in Microsoft Excel spreadsheet file, Additional file [3](#MOESM3){ref-type="media"}.Table 2Sensitivity and specificity---HoloTC versus B~12~---original research dataReferenceSensitivitySpecificityCut-offAUCBamonti et al. ([@CR16])0.740.52HoloTC \< 40 pmol/L0.75Clarke et al. ([@CR31]) (definite deficiency)0.771 versus 0.7570.761 versus 0.724MMA \> 0.75 μmol/L0.85 versus 0.76Clarke et al. ([@CR31]) (probable deficiency)0.647 versus 0.6260.792 versus 0.748MMA \> 0.45 μmol/L0.79 versus 0.87Goringe et al. ([@CR42])HoloTC \< 38 pmol/L0.75 versus 0.72Heil et al. ([@CR46])0.83 versus 0.640.60 versus 0.64MMA \> 0.45 μmol/L0.78 versus 0.70Herrmann et al. ([@CR52])0.87 versus 0.450.75 versus 0.98MMA \> 0.271 μmol/L0.879 versus 0.836Herrmann and Obeid ([@CR51])0.72 versus 0.720.54 versus 0.41MMA \> 0.300 μmol/L0.714 versus 0.632Hvas and Nexo ([@CR59])1.00.89Hvas and Nexo ([@CR60])MMA \> 0.75 μmol/L0.90 versus 0.85Lindemans et al. ([@CR66])MMA \> 0.26 μmol/L0.80 versus 0.68Lloyd-Wright et al. ([@CR69])MMA \> 0.75 μmol/L0.87 versus 0.86Miller et al. ([@CR76])holoTC \< 35 pmol/L0.828 versus 0.816Obeid and Herrmann ([@CR84])0.72MMA \> 0.300 μmol/L0.71 versus 0.60Palacios et al. ([@CR88])0.44 versus 0.200.94 versus 0.94HoloTC \< 35 pmol/L0.75 versus 0.69Schrempf et al. ([@CR94])0.563 versus 0.6620.505 versus 0.621MMA \> 47 μg/L0.66 versus 0.72Scott et al. ([@CR95])MMA \> 0.75 μmol/L0.85 versus 0.75, 0.74, 0.72Valente et al. ([@CR103])0.55 versus 0.330.96 versus 0.95Red cell cobalamin \<33 pmol/L0.90 versus 0.80Clarke et al. ([@CR31]) compared the HoloTC immunoassay to two assay methods for total vitamin B~12~: Beckman and CentaurScott et al. ([@CR95]) compared the HoloTC immunoassay to three assay methods for total vitamin B~12~: Beckman, Centaur and micro assays*AUC*, area under ROC curve for HoloTC or total vitamin B~12~; ROC curve, Receiver Operating Characteristic = sensitivity versus (1 − specificity) = true positive versus false positive (Miller et al. [@CR76]); Cut-off, analyte and cut-off value used to define vitamin B~12~ deficiencyTable 3Sensitivity and specificity---HoloTC versus B~12~---original research conclusionsPositive conclusionsNegative or neutral conclusionsAugoustides-Savvopoulou et al. ([@CR6])Al Aisari et al. ([@CR3])Bhat et al. ([@CR17])Chen et al. ([@CR30])Black et al. ([@CR18])Clarke et al. ([@CR31])Bor et al. ([@CR19])Goringe et al. ([@CR42])Čabarkapa et al. ([@CR23])Loikas et al. ([@CR72])Fragasso et al. ([@CR39])Loikas ([@CR71])Heil et al. ([@CR46])Miller et al. ([@CR76])Herrmann et al. ([@CR52])Nilsson et al. ([@CR83])Herrmann et al. ([@CR54])Palacios et al. ([@CR88])Herrmann and Obeid ([@CR51])Remacha et al. ([@CR92])Hvas and Nexo ([@CR59])Schrempf et al. ([@CR94])Hvas and Nexo ([@CR60])Sobczyńska-Malefora et al. ([@CR100])Lee et al. ([@CR65])van Asselt et al. ([@CR104])Lindemans et al. ([@CR66])Lindgren et al. ([@CR68])Lloyd-Wright et al. ([@CR69])Lobreglio et al. ([@CR70])Morkbak et al. ([@CR78])Nexo et al. ([@CR81])Obeid and Herrmann ([@CR84])Scott et al. ([@CR95])Serefhanoglu et al. ([@CR97])Sikaris ([@CR98])Valente et al. ([@CR103])Vanpoucke et al. ([@CR105])Woo et al. ([@CR108])Positive, neutral or negative conclusions are as understood by this author to be the intention of authors of cited articleQuotations from original reports are available in tables in Microsoft Excel spreadsheet file, Additional file [3](#MOESM3){ref-type="media"}

In March 2012, a group of nine internationally recognised experts issued an *Expert's Consensus Statement* in support of the use of the HoloTC test: "Emerging evidence indicates that holotranscobalamin (Active-B12) is a more reliable marker of a patient's B~12~ status than is serum vitamin B~12~" (Herrmann et al. [@CR55]) (Table [4](#Tab4){ref-type="table"}). However, there is not consensus between all experts, as demonstrated by a report on the NHANES (National Health and Nutrition Survey) roundtable on biomarkers of vitamin B~12~ status (Yetley et al. [@CR109]). The report recommended total vitamin B~12~ as the marker for circulating vitamin B~12~ because of the need for additional performance studies of the HoloTC test.Table 4Signatories to "Expert's Consensus Statement"SignatoryInstitutionWolfgang HerrmannSaarland UniversityRima ObeidSaarland UniversityRalph GreenUniversity of CaliforniaDonald JacobsenCleveland ClinicDominic HarringtonSt. Thomas' HospitalPer Magne UelandUniversity of BergenJan LindemansErasmus Medical CenterEbba NexøAarhus University HospitalAnne MolloyTrinity College DublinFrom Herrmann et al. ([@CR55])Consensus Statement: "Emerging evidence indicates that holotranscobalamin (Active-B12) is a more reliable marker of a patient's B~12~ status than is serum vitamin B~12~"

Reviews, presentations, commentary and letters, on the use of HoloTC as an earlier and more sensitive indicator of vitamin B~12~ deficiency than total vitamin B~12~, have been mixed. Several authors supported the claim that HoloTC was superior (Green [@CR44]; Greibe et al. [@CR45]; Nexo and Hoffmann-Lücke [@CR80]). Others raised concerns about the clinical utility of the test (Carmel [@CR25], [@CR26], [@CR27]; Devalia [@CR32]; Devalia et al. [@CR33]; Hvas and Nexo [@CR61]; Oberley and Yang ([@CR86]). Herrmann et al. ([@CR53]) and Herrmann and Obeid ([@CR49], [@CR50]) recommended the combined use of methylmalonic acid (MMA) and HoloTC. Questioning the superiority of the HoloTC test, Carmel ([@CR25]) stated that "what low holo-TC concentrations really tell us remains elusive."

HoloTC problems {#Sec6}
---------------

There are four problematic aspects of HoloTC, where there are major differences between authors: the value of the half-life of HoloTC; the correlation between HoloTC and total vitamin B~12~; sensitivity of HoloTC to recent absorption of vitamin B~12~; the value of HoloTC cut-off to detect negative vitamin B~12~ balance. The latter two differences are the most important because they raise the questions of what it is that HoloTC concentration actually indicates, and whether or not it is possible to use it to reliably detect the early onset of vitamin B~12~ deficiency.

### Half-life {#Sec7}

Although the proponents of HoloTC, as an early indicator of vitamin B~12~ deficiency, cite the shorter half-life of HoloTC compared to HoloHC as a factor, there is no general agreement on the absolute value (Table [5](#Tab5){ref-type="table"}). In supporting their case for HoloTC, Axis-Shield ([@CR8]) states: "The markedly shorter half-life for HoloTC of 1--2 hours versus 9 days for HoloHC makes a decrease of HoloTC one of the earliest markers of cobalamin deficiency"; Herbert ([@CR48]) gives values of 6 min for HoloTC and 240 h for HoloHC. Whether the half-life of HoloTC is minutes or hours is not significant compared to the generally agreed 240 h for HoloHC. Therefore, although the differences between authors are considerable and should be resolved, they do not invalidate the case for using HoloTC.Table 5Half-life of HoloTCReferenceHalf-life HoloTCAxis-Shield ([@CR8])1--2 hBor et al. ([@CR19])1--12 hCarmel and Agrawal ([@CR28])MinutesChatthanawaree ([@CR29])1 hChen et al. ([@CR30])Few hoursGreen ([@CR43])6 minHerbert ([@CR48])6 minHerrmann et al. ([@CR52])6 minHvas et al. ([@CR62])1--2 hLindgren et al. ([@CR68])1--2 hLoikas et al. ([@CR72])60 minQuadros ([@CR90])1--2 hvon Castel-Roberts et al. ([@CR106])18 h

### Correlation with total vitamin B~12~ {#Sec8}

The correlation between HoloTC and total vitamin B~12~ concentrations, in reports of original research, varies widely between authors (Table [6](#Tab6){ref-type="table"}). Bamonti et al. ([@CR16]) reported a weak correlation (r = 0.42) whereas Augoustides-Savvopoulou et al. ([@CR6]) reported a very strong correlation (r = 0.882). Although most researchers reported a single value for r, there were notable exceptions. Herrmann and Obeid ([@CR51]) reported separate values of r for low or high values of total vitamin B~12~ (r = 0.524 for low B~12~; r = 0.403 for high B~12~). Refsum et al. ([@CR91]) reported separate values for male and female subjects (r = 0.65 for male; r = 0.61 for female). The differences between findings, for correlation coefficient, are important because they reflect different sensitivity and/or specificity relationships between HoloTC and total vitamin B~12~. A very high correlation, over a wide range of values, would imply that HoloTC could not detect the onset of vitamin B~12~ deficiency any earlier than total vitamin B~12~. However, a very low correlation would not necessarily mean that HoloTC is a more sensitive marker of the transition from normal to negative vitamin B~12~ balance.Table 6Correlation between total vitamin B~12~ and HoloTCReferenceHoloTC versus B~12~ correlation coefficient (r)Al Aisari et al. ([@CR3])0.765Augoustides-Savvopoulou et al. ([@CR6])0.882Bamonti et al. ([@CR16])0.42Čabarkapa et al. ([@CR23])0.53Chen et al. ([@CR30])0.45Clarke et al. ([@CR31])0.61Fragasso et al. ([@CR39])0.64Goringe et al. ([@CR42])0.63 (r^2^ = 0.397)Herrmann et al. ([@CR52])0.75Herrmann and Obeid ([@CR51])0.577 (whole), 0.524 (low B~12~), 0.403 (high B~12~)Hvas and Nexo ([@CR60])0.71Lee et al. ([@CR65])0.6591Lloyd-Wright et al. ([@CR69])0.75Lobreglio et al. ([@CR70])0.495Loikas et al. ([@CR72])0.80Loikas ([@CR71])0.78Nexo et al. ([@CR82])0.45Palacios et al. ([@CR88])0.65Refsum et al. ([@CR91])0.65 (male), 0.61 (female)Schrempf et al. ([@CR94])0.577--0.637Scott et al. ([@CR95])0.5Vanpoucke et al. ([@CR105])0.53 (r^2^ = 0.28)Herrmann and Obeid ([@CR51]) reported three values for r: for the whole range of total vitamin B~12~; for low values of vitamin B~12~; for high values of vitamin B~12~Refsum et al. ([@CR91]) reported separate values for r for males and females

### Sensitivity to recent absorption {#Sec9}

The reported sensitivity of the HoloTC concentration to recent absorption of vitamin B~12~ varies between authors (Table [7](#Tab7){ref-type="table"}), leading to the important question about whether HoloTC concentration indicates long-term status or recent absorption of vitamin B~12~ or both. Axis-Shield and Abbott Laboratories (Axis-Shield and Abbott Laboratories [@CR12], [@CR14]; Axis-Shield [@CR7]) cite Chen et al. ([@CR30]), stating that HoloTC reflects vitamin B~12~ status "independent of recent absorption of the vitamin". Chen et al. ([@CR30]) actually concluded that "Metabolic cobalamin status is a major determinant of serum holo-TC II. Absorption status may have mild influence as well". Axis-Shield ([@CR9]) cite Nexo: "newly absorbed vitamin B~12~ occurs as holoTC, and therefore an increase in holoTC upon oral loading with vitamin B~12~ can be used to judge the capacity for uptake of the vitamin". Several authors found the issue to be problematic (Bamonti et al. [@CR16]; Loikas [@CR71]; Carmel [@CR25], [@CR27]). Bamonti et al. ([@CR16]) cited the conflicting findings of Chen et al. ([@CR30]) and Bor et al. ([@CR19]). Loikas ([@CR71]) commented on the apparently contradictory promotion of HoloTC as "the most sensitive and specific indicator of early vitamin B~12~ deficiency" and the proposed use of HoloTC as "a marker of vitamin B~12~ absorption", concluding that "Reconciling these two phenomena is problematic because, although frequently coexisting, they are not identical". In his editorial, Carmel ([@CR25]) observed that "The favoured hypotheses have been that low holo-TC is either an early sign of general cobalamin insufficiency or specific evidence of decreased absorption of cobalamin. The distinction between these two very separate explanations has blurred, particularly as advocacy became more enthusiastic, but it is not an idle distinction. This central issue and many other questions need resolution".Table 7Sensitivity to recent absorptionReferenceDependence on recent absorptionAxis-Shield and Abbott Laboratories ([@CR12])IndependentAxis-Shield and Abbott Laboratories ([@CR14])IndependentAxis-Shield ([@CR7])IndependentAxis-Shield ([@CR9])DependentBamonti et al. ([@CR16])ProblematicBhat et al. ([@CR17])DependentBor et al. ([@CR19])DependentBor et al. ([@CR20])DependentCarmel ([@CR25])ProblematicCarmel ([@CR27])ProblematicChen et al. ([@CR30])Both?Green ([@CR44])BothHvas et al. ([@CR62])IndependentHvas et al. ([@CR63])DependentIBL International ([@CR64])IndependentLindgren et al. ([@CR68])DependentLoikas ([@CR71])ProblematicMorkbak et al. ([@CR77])DependentNexo et al. ([@CR81])DependentNexo and Hoffmann-Lücke ([@CR80])BothRobinson et al. ([@CR93])Bothvon Castel-Roberts et al. ([@CR106])DependentQuotations from original reports are available in tables in Microsoft Excel spreadsheet file, Additional file [3](#MOESM3){ref-type="media"}

### No agreed cut-off {#Sec10}

Another important problem is that there is no agreement on a single value for the cut-off level for the minimum concentration of HoloTC, as required to distinguish between normal vitamin B~12~ status and the first stage of deficiency (Table [8](#Tab8){ref-type="table"}). Morkbak et al. ([@CR77]) quoted a range of 11--41 pmol/L for eight European studies, stating: "There is no consensus concerning the choice of reference intervals for holoTC". According to Heil et al. ([@CR46]): "large discrepancies exist with regard to the choice of cut-off value for HoloTC (range 20--45 pmol/L), which mak*es data* interpretation difficult". In their review, Aparicio-Ugarriza et al. ([@CR5]) found that, in 69 studies between 1992 and 2014, researchers quoted HoloTC concentration cut-offs from 20 to 50 pmol/L.Table 8HoloTC reference intervals and cut-offsReferenceReference interval (pmol/L)Cut-off (pmol/L)Abbott Laboratories ([@CR1])37Abbott Laboratories ([@CR2])35Al Aisari et al. ([@CR3])9--123Aparicio-Ugarriza et al. ([@CR5])20--50 (literature review)Augoustides-Savvopoulou et al. ([@CR6])35Axis-Shield and Abbott Laboratories ([@CR12])35Axis-Shield ([@CR7])35Axis-Shield ([@CR8])37Bamonti et al. ([@CR16])40Black et al. ([@CR18])23--100Brady et al. ([@CR01])35Chen et al. ([@CR30])46--35630Clarke et al. ([@CR31])45Fragasso et al. ([@CR39])35Goringe et al. ([@CR42])16 (diagnostic), 38 (laboratory)Green ([@CR43], [@CR44])35Heil et al. ([@CR46])32Herbert ([@CR47])22Herbert ([@CR48])37Herrmann et al. ([@CR52], [@CR53], [@CR54])35Herrmann and Obeid ([@CR49])40--70 "Grey zone"Herrmann and Obeid ([@CR50])35Herrmann and Obeid ([@CR51])22--76 "Grey zone"Herrmann et al. ([@CR52])35Herrmann et al. ([@CR54])35Hooshmand et al. ([@CR58])35Hvas and Nexo ([@CR59])50Hvas and Nexo ([@CR60])40Lee et al. ([@CR65])42.48Lindemans et al. ([@CR66])20--122Lindgren et al. ([@CR68])35--160Lloyd-Wright et al. ([@CR69])\<25 likely, \>50 unlikely B~12~ deficiencyLobreglio et al. ([@CR70])35Loikas et al. ([@CR72], [@CR73], [@CR74])37Loikas ([@CR71])37--171Miller et al. ([@CR76])35Morkbak et al. ([@CR77])40, 11--41 (literature review)37Morkbak et al. ([@CR78])40--150Nexo et al. ([@CR81])40--150Nexo et al. ([@CR82])40--150Nexo and Hoffmann-Lücke ([@CR80])40--200Obeid and Herrmann ([@CR84], [@CR85])35Palacios et al. ([@CR88])35Pry ([@CR89])37Refsum et al. ([@CR91])42--157Remacha et al. ([@CR92])33.5Schrempf et al. ([@CR94])42Serefhanoglu et al. ([@CR97])37Sobczyńska-Malefora et al. ([@CR100])25--50 "poor predictor MMA"Valente et al. ([@CR103])20--30 "indeterminate zone"20van Asselt et al. ([@CR104])38--113Vanpoucke et al. ([@CR105])37Woo et al. ([@CR108])35

Furthermore, several researchers quote a *grey zone*, or indeterminate range of cut-off values for HoloTC concentration (Table [8](#Tab8){ref-type="table"}). Herrmann and Obeid ([@CR49]) quote a *grey zone* for HoloTC cut-offs, of 40--70 pmol/L; they later changed this to 23--75 pmol/L (Herrmann and Obeid [@CR51]). Lloyd-Wright et al. ([@CR69]) say that deficiency is likely for a HoloTC concentration \<25 pmol/L, and unlikely for \>50 pmol/L, leaving an indeterminate range of 25--50 pmol/L. Sobczyńska-Malefora et al. ([@CR100]) found that HoloTC concentrations in the range of 25--50 pmol/L could not be used to predict the vitamin B~12~ status as defined by MMA concentration. Valente et al. ([@CR103]) reported an *indeterminate zone* of 20--30 pmol/L for HoloTC concentrations. In their BJH guideline, Devalia et al. ([@CR33]) recommended that "Serum holotranscobalamin has the potential as a first-line test, but an indeterminate 'grey area' may still exist".

The HoloTC test appears to suffer from a similar limitation to that found for total vitamin B~12~; the range of normal values for an individual is much narrower than the range of normal for a population (Herbert [@CR47]). According to McCaddon et al. ([@CR75]), referring to the HoloTC test: "the dispersion of values for any individual will span only a small part of any reference interval".

The absence of an agreement on a single cut-off value for HoloTC, for diagnosis of vitamin B~12~ deficiency, is inconsistent with a widely stated reason for supporting the use of this test in place of total vitamin B~12~: that there is a wide indeterminate range for total vitamin B~12~. In promoting their HoloTC assay, Axis-Shield ([@CR7]) state this inadequacy of the total vitamin B~12~ test: "There is a grey zone between approximately 151--300 pmol/L B~12~ where there is likely to be misclassification of B~12~ status if relying on total serum B~12~ alone." If there is no universally agreed single cut-off value for a minimum HoloTC concentration, this test appears to have the same flaw as total vitamin B~12~. Is it possible to reliably detect the early onset of vitamin B~12~ deficiency, i.e. the transition between Herbert's sequential stages from *Normal* to *Early Negative B*~12~*Balance*, if there is no agreed single cut-off value for HoloTC?

Potential for data manipulation to promote HoloTC {#Sec11}
-------------------------------------------------

### Area Under Curve (AUC) {#Sec12}

Where the Area Under Curve (AUC) is reported for Receiver Operating Characteristic (ROC) curves, the selection of the reference analyte and value of the reference cut-off determines the relative areas under the curve (Table [2](#Tab2){ref-type="table"}). For example, Heil et al. ([@CR46]) produced three ROC curves where different cut-off levels of MMA were used to define vitamin B~12~ deficiency, demonstrating how the choice of reference cut-off level determines the difference in AUC for HoloTC compared to total vitamin B~12~. With the lowest MMA cut-off, of \>0.32 µmol/L, the AUC was 0.70 for HoloTC, compared to 0.63 for total vitamin B~12~. At their preferred MMA cut-off, of \>0.45 µmol/L, the AUC was 0.78 for HoloTC, compared to 0.70 for total vitamin B~12~. When the MMA cut-off was increased to \>0.77 µmol/L, the AUC was 0.92 for HoloTC, compared to 0.73 for total vitamin B~12~.

By increasing the MMA cut-off, the difference in AUC between HoloTC and total vitamin B~12~ is increased (Heil et al. [@CR46], Figure 1), improving the apparent performance of HoloTC, but many more vitamin B~12~ deficient patients will be misdiagnosed as normal. The next stage of the process, selection of the total vitamin B~12~ and HoloTC cut-offs, is a trade-off between sensitivity and specificity (Heil et al. [@CR46], Figure 4).

### The trade-off between sensitivity and specificity {#Sec13}

As noted by this author (Golding [@CR41]), it is possible to alter the apparent relative sensitivity of any pair of analytes by selectively changing the cut-off value of one or both of them. As demonstrated in that experiment, selecting different cut-off values for total vitamin B~12~ changed the relative sensitivities of HoloTC and total vitamin B~12~; the same applies to the cut-off value for HoloTC. When the HoloTC cut-off is increased, the sensitivity to vitamin B~12~ deficiency is increased, but the specificity of the test is reduced, increasing the number of false positive results. Conversely, if the HoloTC cut-off is decreased, the specificity of the test is increased, but the sensitivity of the test is reduced, increasing the number of false negative results.

From their ROC charts, Heil et al. ([@CR46], Figure 3) selected MMA \> 0.45 µmol/L to define vitamin B~12~ deficiency. With a HoloTC cut-off value of \<21 pmol/L, the specificity was impressively high at 88 % but the sensitivity was only 64 % (Heil et al. [@CR46], Figure 4b). By selecting the best trade-off between sensitivity and specificity for HoloTC, with a HoloTC cut-off value of \<32 pmol/L, they obtained an impressive HoloTC sensitivity of 83 % but a specificity of only 60 %. To overcome this problem, as did Herrmann and Obeid ([@CR49], [@CR50]), the authors suggest using MMA as a secondary test to confirm vitamin B~12~ deficiency in cases where HoloTC is \<32 pmol/L. This approach would have failed to detect any vitamin B~12~ deficiency in the subject of this author's experiment (Golding [@CR41]) because, despite overt metabolic disturbance evident from raised MMA concentration, and the onset of severe symptoms including peripheral neuropathy, HoloTC concentration never fell below 33 pmol/L.

Contrary findings {#Sec14}
-----------------

The results of several studies did not support the claims that HoloTC is a significantly earlier marker of vitamin B~12~ deficiency than total B~12~ (Clarke et al. [@CR31]; Palacios et al. [@CR88]; Schrempf et al. [@CR94]; Miller et al. [@CR76]; Remacha et al. [@CR92]). This author, in his single-subject self-experiment, reported no significant difference in response between HoloTC and total vitamin B~12~ (Golding [@CR41]).

Contrary to Heil et al., Schrempf et al. ([@CR94]) reported a lower AUC for HoloTC than for total vitamin B~12~; 0.563 versus 0.662 (Table [2](#Tab2){ref-type="table"}). Their study was conducted on neuropsychiatric patients with vitamin B~12~ deficiency defined by MMA \> 47 µg/L (40 µmol/L). The authors presented the ROC curves for three patient groups: all patients; those with classic vitamin B~12~ deficiency (subacute combined degeneration and/or peripheral neuropathy); those with peripheral neuropathy only. In each grouping, the AUC for total vitamin B~12~ was greater than for HoloTC (Schrempf et al. [@CR94], Figure 1).

Based on their ROC results, in which the AUCs for HoloTC and total vitamin B~12~ were 0.828 and 0.816 respectively, Miller et al. ([@CR76]) concluded that "HoloTC and total vitamin B12 have equal diagnostic accuracy in screening for metabolic vitamin B~12~ deficiency". They also reported correlations between their results, for HoloTC and total vitamin B~12~, which were not consistent with Herbert's model. For example, some patients with normal HoloTC (\>35 pmol/L) were low in total vitamin B~12~ (\<148 pmol/L).

As observed by Herrmann and Obeid ([@CR51]), in reporting results of their investigation of the biological markers of vitamin B~12~ deficiency, "The shape of the ROC curve illustrates that the holoTC test is not sufficient to separate between deficient and non-deficient individuals with high reliability".

Remacha et al. ([@CR92]) investigated 106 patients with total vitamin B~12~ concentration ≤200 pmol/L, defining low HoloTC as a concentration \<33.5 pmol/L and high MMA as a concentration \>0.40 µmol/L. Of the 31 patients with normal HoloTC concentrations, 13 had high levels of MMA; of the 75 patients with low HoloTC concentrations, 27 had normal MMA. Remacha et al. reported that "HoloTC was not decreased in one-third of patients with low Cbl, but MMA/Hcy levels were elevated in half of them, reflecting Cbl deficiency."

The problems with Herbert's model {#Sec15}
---------------------------------

The absence of an agreed single value for the HoloTC cut-off, together with uncertainty about whether HoloTC represents recent absorption of vitamin B~12~ or long-term status or both, must raise questions about Herbert's hypothesis. Some of the most recent original research challenges Herbert's model for the "Sequential stages in the development of vitamin B~12~ deficiency". In reporting their original research results, Remacha et al. ([@CR92]) commented that "These data do not support holoTC as the earliest marker of Cbl deficiency and challenge the classification in stages of Cbl deficiency".

In Herbert's revised 1994 model (Herbert [@CR48]), the change from *Normal* to Early *Negative Vitamin B*~12~*Balance* is marked by a fall in HoloTC concentration from \>37 to \<30 pmol/L. Even if it is assumed that such a highly precise and accurate routine clinical assay is possible, there remain two major unresolved fundamental problems with Herbert's hypothesis.

Firstly, as raised by several authors, there is uncertainty about what HoloTC actually represents (Table [7](#Tab7){ref-type="table"}). Does HoloTC concentration indicate recent absorption of vitamin B~12~, long-term body store or both? As stated by Chen et al. ([@CR30]): "The concept that a test can be used to diagnose both deficiency and malabsorption is problematic because the 2 defects are not identical. If holo-TC II truly reflects both processes, holo-TC II changes would perforce lose all diagnostic specificity for either process". For the HoloTC immunoassay to have any clinical value in detecting the earliest onset of vitamin B~12~ deficiency, as Herbert intended, it would need to be either sensitive only to long-term status or be performed after a well-defined period of fasting.

Secondly, the model demands the reliable detection of a change in HoloTC concentration far smaller than the reported range of cut-off values (Table [8](#Tab8){ref-type="table"}). As noted by Sobczyńska-Malefora et al. ([@CR100]), "there has been little consensus with regard to the assigned cut-off to discriminate between replete and deficient states". Herbert's required change in HoloTC concentration from \>37 to \<30 pmol/L, to detect the earliest onset of vitamin B~12~ deficiency, is inconsistent with the reported range of cut-off values from 20 to 50 pmol/L. Furthermore, the use of various *grey zones*, for HoloTC concentration (Table [8](#Tab8){ref-type="table"}), is inconsistent with Herbert's hypothesis in which *Early Negative Vitamin B*~12~*Balance* is detected by a universally agreed, and closely specified, fall in HoloTC concentration.

Why Herbert's model is flawed {#Sec16}
-----------------------------

Herbert's model for the staged development of vitamin B~12~ deficiency is based on his erroneous hypothesis that HoloTC will always be the first analyte to respond to a deficiency, and that a minimum normal concentration of HoloTC may be universally defined. How Herbert developed his hypothesis, and why it is flawed, is best explained by examining the process of gastrointestinal absorption and transport of vitamin B~12~ in humans.

### Normal gastrointestinal absorption of vitamin B~12~ {#Sec17}

Figure [3](#Fig3){ref-type="fig"} is a simplified diagram containing the main elements of the process of gastrointestinal absorption and transport of vitamin B~12~ in humans. In a healthy person, stomach acid separates food vitamin B~12~ from protein; haptocorrin (HC) from saliva then binds with the free vitamin B~12~ to form the holohaptocorrin (HoloHC) (Loikas [@CR71], Figure 2.4). The increased pH in the duodenum causes the vitamin B~12~ to be released from the HC; intrinsic factor (IF), produced by parietal cells in the stomach, combines with the vitamin B~12~ in the duodenum to produce IF-B12 (Loikas [@CR71], Figure 2.4). The IF is then degraded in the terminal ileum, producing free vitamin B~12~ (Seetharam and Yammani [@CR96], Figure 1; Andrès et al. [@CR4], Figure 1; Loikas [@CR71], Figure 2.4).Fig. 3Vitamin B~12~ gastrointestinal absorption. Derived from Seetharam and Yammani ([@CR96], Figure 1), Andrès et al. ([@CR4], Figure 1) and Loikas ([@CR71], Figure 2.4)

There is no consensus on the exact location of the production of HoloTC and HoloHC.

According to Seetharam and Yammani ([@CR96], Figure 1), and Andrès et al. ([@CR4], Figure 1), the free B~12~ is bound to TC in the ileum to form HoloTC; they show HoloHC in the portal vein but do not say how or where it is formed. Quadros ([@CR90]) states that "The IF-Cbl absorbed in the distal ileum appears in the circulation bound to TC", implying that all of the free B~12~ is bound to TC to form HoloTC; it is unclear from this whether the free B~12~ binds to the TC in the ileum or in the circulation. According to Furger ([@CR40]) "In the blood plasma Cbl is bound either to HC or TC, where only TC is responsible for the Cbl uptake into cells"; again, it is unclear where the binding takes place. If all of the free vitamin B~12~ in the ileum is bound to TC, regardless of whether the binding takes place in the ileum or in the circulation, then the HoloHC in the circulation must ultimately be produced from vitamin B~12~ freed from the HoloTC.

The HoloTC enters the general circulation from where it is delivered to cells for metabolism (Seetharam and Yammani [@CR96], Figure 1; Andrès et al. [@CR4], Figure 1; Loikas [@CR71], Figure 2.4; Quadros [@CR90]; Furger [@CR40]).

The HoloHC is passed, via the portal vein, to the liver where the vitamin B~12~ is separated from the HC and stored in the liver (Seetharam and Yammani [@CR96], Figure 1). When HoloTC is required for metabolism, some of the vitamin B~12~ stored in the liver is bound to HC and recycled via the bile (Seetharam and Yammani [@CR96], Figure 1; Loikas [@CR71], Figure 2.4).

### Normal enterohepatic recycling of vitamin B~12~ {#Sec18}

Of crucial importance to this entire gastrointestinal absorption process is the enterohepatic recycling of the vitamin B~12~, shown in Fig. [3](#Fig3){ref-type="fig"} as the transfer of HoloHC from the liver to the duodenum, in the bile. This recycling is not only essential for the efficient maintenance of the body store of vitamin B~12~; it is the means by which the serum concentration of HoloTC is regulated. The rate of transfer to the duodenum of HoloHC in bile, and the IF from the parietal cells, controls the rate of HoloTC production.

This enterohepatic recycling process is shown, as a feedback control system, in Fig. [4](#Fig4){ref-type="fig"}. Here, the *Input* to the system is the intrinsic factor; the system *Output* is the HoloTC. The *Process* is the production of IF-B12 from the IF and vitamin B~12~ in the duodenum, and the binding of the B~12~ freed from IF in the terminal ileum with transcobalamin (TC) to produce holotranscobalamin (HoloTC). For the purposes of this discussion, the liver vitamin B~12~ store is not part of the input but considered to be a constant in the short-term. The *Feedback* signals control the rate of the process; details of the nature of these signals are beyond the scope of this review.Fig. 4HoloTC feedback control. Derived from Seetharam and Yammani ([@CR96], Figure 1), Andrès et al. ([@CR4], Figure 1) and Loikas ([@CR71], Figure 2.4)

### Failure of enterohepatic recycling and HoloTC production {#Sec19}

If any one of the elements of this feedback control system suddenly fails entirely, the enterohepatic recycling will stop immediately, and no HoloTC will be produced; for example, if the supply of intrinsic factor or production of bile suddenly stops or if the terminal ileum or duodenum are removed. Under these circumstances, Herbert's hypothesis would be expected to hold true in one respect; the fall in HoloTC would be an early indicator of a vitamin B~12~ deficiency. The HoloHC has a far longer half-life than the HoloTC in serum, and there is a large store of vitamin B~12~ in the liver and red-cells, so HoloHC would fall much more slowly than HoloTC.

It is important to note that only a disturbance of the IF input, or of elements within this HoloTC feedback system, will affect its short-term performance. Assuming that the liver vitamin B~12~ store is full, any failure ahead the input of IF, or after the output of HoloTC will have no short-term effect on the production of HoloTC. This means that HoloTC will not be an early responder for all causes of vitamin B~12~ deficiency; if the enterohepatic cycle is not disrupted, HoloTC would remain normal until the liver store of HoloHC is exhausted.

### HoloTC response depends on cause of vitamin B~12~ deficiency {#Sec20}

The following discussion is based on this author's interpretation of available information about the operation of the vitamin B~12~ enterohepatic cycle, and the response of total vitamin B~12~, HoloTC, tHcy and MMA for different causes of vitamin B~12~ deficiency. Human experimentation is needed to investigate the actual responses of the analytes under these various conditions.

According to Herbert ([@CR47], [@CR48]), there are six possible causes of vitamin B~12~ deficiency; three inadequacies and three excesses. These conditions, and their effect on the HoloTC feedback system, are listed in Table [9](#Tab9){ref-type="table"}. A seventh very common cause of vitamin B~12~ deficiency, food-cobalamin malabsorption, was reported by Carmel ([@CR24]) and reviewed by Andrès et al. ([@CR4]); this is shown in Table [9](#Tab9){ref-type="table"} as a fourth inadequacy.Table 9Causes of vitamin B12 deficiency, and short-term effect on HoloTC productionCause of vitamin B12 deficiencyClassificationShort-term effect on HoloTC production?Inadequate dietary intakeInadequacyNoDefective gastrointestinal absorption (other than food-cobalamin absorption)InadequacyYes?Defective gastrointestinal absorption (food-cobalamin malabsorption)InadequacyNoInadequate cellular utilization (deficiency of a cobalamin coenzyme)InadequacyNoIncreased requirement (pregnancy or hyperthyroidism)ExcessNoIncreased excretion (alcoholism)ExcessNoIncreased destruction (nutrient or drug interactions)ExcessNo, unless intrinsic factor destroyedFrom Herbert ([@CR47], [@CR48]), Carmel ([@CR24]) and Andrès et al. ([@CR4])

A suddenly inadequate dietary intake, for example commencing a vegan diet, will not affect the enterohepatic cycle because it does not affect the input of intrinsic factor into the cycle until the store of HoloHC is exhausted i.e. it occurs ahead of the cycle. Similarly, the onset of inadequate utilization in the cells also will not affect the production of HoloTC i.e. it occurs after the cycle. In either case, Herbert's model will not apply because total vitamin B~12~ will fall before HoloTC responds, and MMA and tHcy will commence to increase immediately after HoloTC falls below normal for the individual.

An increased requirement, increased excretion or increased destruction, would tend to cause an increase in the rate of enterohepatic recycling to maintain the serum concentration of HoloTC; if all else is equal, the cycle will continue to produce HoloTC until the supply of stored HoloHC is consumed. Again, Herbert's model will not hold true because total vitamin B~12~ will fall before HoloTC responds, and MMA and tHcy will commence to increase immediately after HoloTC falls below normal for the individual.

One inadequacy, gastrointestinal malabsorption, affecting the supply of intrinsic factor, production of bile or absorption of the IF-B12, has the potential to halt HoloTC production. HoloTC is likely to be a fast responder to a rapid failure such as the removal of the relevant part of the stomach, containing the parietal cells, or the removal of the duodenum or terminal ileum. In this case, however, MMA and tHcy would be expected to almost immediately increase above normal for the individual, so there would be no period when HoloTC is depleted without any metabolic disturbance, and Herbert's model would not hold true.

If there is a gradual failure of supply of intrinsic factor to the input, in the case of Pernicious Anaemia where the autoimmune disease causes antibodies to attack the parietal cells or intrinsic factor or other slowly developing problem with gastrointestinal vitamin B~12~ absorption, the metabolic disturbance would again commence immediately but MMA and tHcy would increase more slowly. Again, because there would be no period when HoloTC is depleted without any metabolic disturbance, Herbert's model would not apply.

The very common case of food-cobalamin malabsorption, where gastric atrophy occurs during ageing, was first identified after Herbert proposed his model (Carmel [@CR24]; Andrès et al. [@CR4]). This case would be similar to that of inadequate dietary intake, where the enterohepatic cycle is not disturbed because there is no effect on the input of intrinsic factor into the cycle until the liver store of HoloHC is exhausted. Because the deficiency occurs ahead of the cycle, there would be no period when HoloTC is depleted without any metabolic disturbance, so Herbert's model would not hold true. If the slow onset of vitamin B~12~ deficiency in this case does cause HoloTC to fall significantly, and remain depleted before other analytes react, the published experimental results should demonstrate this. According to Andrès et al. ([@CR4]), \>60 % of cases of vitamin B~12~ deficiency in the elderly are caused by food-cobalamin malabsorption. The studies reported by Miller et al. ([@CR76]), Clarke et al. ([@CR31]), Schrempf et al. ([@CR94]), Palacios et al. ([@CR88]) and Remacha et al. ([@CR92]) all involved aged patients, so the majority were therefore likely to have their vitamin B~12~ deficiency caused by food-cobalamin malabsorption. If Herbert's model applied to those patients, HoloTC should have been reported as significantly more sensitive than total vitamin B~12~, but this was not the case in those studies.

An alternative hypothesis {#Sec21}
=========================

Introduction {#Sec22}
------------

This author proposes an alternative model (Fig. [5](#Fig5){ref-type="fig"}) in which the earliest onset of vitamin B~12~ deficiency, or the transition from *Normal* to *Early Negative Vitamin B*~12~*Balance*, is not defined by a fall in HoloTC concentration from above one universally specified level to below another. Instead, vitamin B~12~ deficiency is defined by a change, in total vitamin B~12~, HoloTC or metabolite concentrations, from what is normal for the individual.Fig. 5Alternative model for the development of vitamin B~12~ deficiency. Total B~12~, serum total vitamin B~12~ concentration; HoloTC, serum holotranscobalamin concentration; MMA, plasma methylmalonic acid concentration; tHcy, plasma total homocysteine concentration

Stages of development of vitamin B~12~ deficiency {#Sec23}
-------------------------------------------------

The alternative model for the development of vitamin B~12~ deficiency contains only three stages: *Normal*; *Depletion*; *Metabolic Deficiency* (Fig. [5](#Fig5){ref-type="fig"}). The *Normal* stage is defined as the condition in which the intake, and the internal processing, for an individual provides sufficient vitamin B~12~ to sustain all of their metabolic requirements and maintain their body store of vitamin B~12~. The *Depletion* stage, marked by the commencement of a long-term fall in serum total vitamin B~12~ concentration, is defined as the condition in which the intake, or the internal processing, for an individual does not provide sufficient vitamin B~12~ to sustain all of their metabolic requirements, which are then maintained by depleting their body store of vitamin B~12~. The *Metabolic Deficiency* stage, marked by the commencement of a fall in the HoloTC concentration and an increase in either MMA or tHcy or both metabolites, is defined as the condition in which the depleted body store of vitamin B~12~, or the internal processing, for an individual is insufficient to sustain all of their metabolic requirements.

Cellular storage of vitamin B~12~ and potential delays in metabolic response to fall in HoloTC {#Sec24}
----------------------------------------------------------------------------------------------

Herbert ([@CR48]) stated: "holoTCII will always be low before there is a rise in methylmalonate or homocysteine if that rise is due to a vitamin B-12 deficiency." This alternative model proposes an additional principle; that any fall in HoloTC, to below normal for the individual, must result in a disturbed metabolism and a rise in the metabolites. How quickly this happens depends on how much vitamin B~12~ is stored in the cells; this varies between cell types; some cells, including nerve cells and some blood cells, have very small vitamin B~12~ stores. For example, as stated by Herbert ([@CR48]) "Lack of delivery of vitamin B-12 to the glial cells of the brain quickly wipes out their small vitamin B-12 stores, after which they become vitamin B-12 deficient".

This alternative hypothesis therefore assumes that, for at least some cell types, there will be no significant delay between the fall in HoloTC concentration to below normal for the individual, and the rise in MMA and/or tHcy. This is consistent with Herbert ([@CR47]) where, in referring to the timing of a fall in HoloTC and the development of neutrophil hypersegmentation, he states that: "when one follows individuals from B-12 normality into the earliest stages of B-12 deficiency, one discovers that both fall almost together in the individual. The amount of B-12 on the B-12 delivery protein transcobalamin II falls sharply and, at almost the same time (probably fractionally later), DNA synthesis becomes subnormal in the granulocytes." Even if not all cells are affected immediately, and if the MMA and/or tHcy are not yet measurably abnormally high, the metabolism for some cell types has been disturbed. Thus in this alternative model, almost immediately after the HoloTC production falls below normal for any reason, the *Depletion* stage ends and the *Metabolic Deficiency* stage commences.

Dependence of timing of HoloTC response on cause of vitamin B~12~ deficiency {#Sec25}
----------------------------------------------------------------------------

The magnitude and speed of any change in HoloTC concentration depends on the cause of the onset of vitamin B~12~ deficiency, as well as individual variables involved in the absorption, transport and utilization of vitamin B~12~. Three possible cases of disruption to the enterohepatic cycle are considered here: failure only after exhaustion of vitamin B~12~ liver store; instantaneous failure; gradual failure. The following discussion is based on this author's hypothesis about how the response of total vitamin B~12~, HoloTC, tHcy and MMA depends on the cause of vitamin B~12~ deficiency. Human experimentation is needed to validate this model.

### Failure only after exhaustion of vitamin B~12~ liver store {#Sec26}

When there is no short-term disruption to the enterohepatic cycle, HoloTC concentration will be maintained until there is insufficient holohaptocorrin remaining to sustain HoloTC production. This case contains all stages of the general model, as shown in Fig. [5](#Fig5){ref-type="fig"}, where there is a significant *Depletion* period before the eventual failure of the enterohepatic cycle leads to the onset of *Metabolic Deficiency*. The total vitamin B~12~ falls, but HoloTC, MMA and tHcy remain normal, during the *Depletion* period. When the liver store of HoloHC is consumed, *Metabolic Deficiency* commences, with the HoloTC concentration falling and the MMA and tHcy increasing. This case applies where the failure is outside of the HoloTC feedback control loop (Fig. [4](#Fig4){ref-type="fig"}), for example when the vitamin B~12~ deficiency is caused by reduction in intake, or reduction in the utilization of the vitamin B~12~ in the cells because of a defect in the intracellular cobalamin metabolism. Another, very common, example of this case is food-cobalamin malabsorption where vitamin B~12~ bound to food protein cannot be released because of hypochlorhydria due to gastric atrophy (Carmel [@CR24]; Andrès et al. [@CR4]). This common cause of vitamin B~12~ deficiency in the elderly is not the same as pernicious anaemia because production of intrinsic factor is not affected; the patient is able to absorb unbound vitamin B~12~. Examples of such cases consistent with this alternative model, where vitamin B~12~ deficiency was likely to be caused by gradual loss of gastric acid production, were those whose subjects were elderly (Miller et al. [@CR76]; Clarke et al. [@CR31]; Schrempf et al. [@CR94]; Palacios et al. [@CR88]; Remacha et al. [@CR92]).

### Instantaneous failure {#Sec27}

If the production of HoloTC suddenly halts, because of an instantaneous failure of the enterohepatic cycle, for example as a result of the surgical removal of the parietal cells of the stomach, an extreme case of the proposed model will apply. As shown in Fig. [6](#Fig6){ref-type="fig"}, the sudden loss of HoloTC will cause an almost immediate metabolic disturbance and a rise in the concentration of MMA and/or HoloTC. Thus, there will be no *Depletion* period in this case, because MMA and/or tHcy will respond almost instantaneously to the fall in HoloTC concentration, and the *Metabolic Deficiency* stage commences almost immediately.Fig. 6Instantaneous failure of enterohepatic recycling. Total B~12~, serum total vitamin B~12~ concentration; HoloTC, serum holotranscobalamin concentration; MMA, plasma methylmalonic acid concentration; tHcy, plasma total homocysteine concentration

### Gradual failure {#Sec28}

Figure [7](#Fig7){ref-type="fig"} illustrates the case where the production of HoloTC gradually fails, for example as a result of loss of parietal cell function due to the autoimmune disease pernicious anaemia. As for the case of instantaneous failure, there is no *Depletion* period, and the *Metabolic Deficiency* stage commences almost immediately, because MMA and/or tHcy will start to increase immediately after the HoloTC concentration falls below the normal level for the individual. The difference in this case is that the rate of change of the analytes will be slower than when the supply of intrinsic factor is suddenly stopped.Fig. 7Gradual failure of enterohepatic recycling. Total B~12~, serum total vitamin B~12~ concentration; HoloTC, serum holotranscobalamin concentration; MMA, plasma methylmalonic acid concentration; tHcy, plasma total homocysteine concentration

Consequences of questioning Herbert's model {#Sec29}
-------------------------------------------

Questioning of Herbert's hypothesis that HoloTC is the most sensitive marker of *Early Negative Vitamin B*~12~*Balance*, or his model for the sequential stages in the development of vitamin B~12~ deficiency, is likely to raise strong objections.

Firstly, any model that is based on changes from individual normal analyte concentrations, instead of comparison with a universally accepted population normal, conflicts with the dogma that there must be a *gold*-*standard* test for vitamin B~12~ deficiency; either HoloTC or one a yet to be discovered.

Secondly, any model that requires a comparison of current analyte concentrations with a patient's own normal levels would require proactive testing of all persons at risk, before the onset of any symptoms, to obtain their individual healthy baseline concentrations. Herbert himself suggested proactive testing, saying "serum holoTCIl should be measured every 5 y starting at age 55 because gradual loss of the ability to absorb vitamin B-12 occurs in everyone in a genetically determined, age-dependent pattern." (Herbert [@CR48]).

A potential alternative to obtaining a longitudinal record for individuals at risk is the use of an algorithm to combine the results of a one-off test of all four analytes into a single parameter. A mathematical model for this has been devised and described in detail by Fedosov ([@CR36]), and further tested and refined (Fedosov [@CR37]; Fedosov et al. [@CR38]; Brito et al. [@CR22]). This author is cautious about this approach because, as with all other current methods, it might apply well to a population but not necessarily to an individual. This would need extensive testing on a wide range of subjects, for various causes of vitamin B~12~ deficiency, before it could be validated.

Summary and conclusion {#Sec30}
======================

Axis-Shield and others, in promoting the commercialisation of the HoloTC immunoassay, have relied on Herbert's erroneous hypothesis that "Ho1oTCII falls below the bottom of its normal range long before total serum vitamin B-12 ... falls below the bottom of its normal range", and his flawed model for the staged development of vitamin B~12~ deficiency (Herbert [@CR48]).

Herbert's model is flawed because it assumes that a normal minimum concentration for HoloTC may be universally defined. As with total vitamin B~12~, evidenced by the failure to find such a single cut-off value for HoloTC and instead the discovery of a wide *grey zone* for HoloTC, the range of normal for an individual is much smaller than for the population. As stated by Herbert ([@CR48]): "What is normal for one is not normal for another".

Herbert's hypothesis, that HoloTC will respond early to vitamin B~12~ depletion, before the onset of a clinical deficiency, is erroneous because it does not take into account how enterohepatic recycling regulates the HoloTC concentration. Where the cause of vitamin B~12~ deficiency does not disrupt the enterohepatic cycle, HoloTC will not be an early responder to a deficiency; there will be a *Depletion* period, in which total vitamin B~12~ falls, but HoloTC and the metabolites will only respond after the liver store is exhausted. When the cause of vitamin B~12~ deficiency does disrupt the enterohepatic cycle, the HoloTC will be an early responder but there will be no *Depletion* period; the metabolites will respond quickly when HoloTC falls below normal for the individual.

The HoloTC immunoassay cannot be used to measure vitamin B~12~ status any more reliably than total vitamin B~12~, or to predict the onset of a metabolic deficiency, because it is based on an erroneous hypothesis and a flawed model for the staged development of vitamin B~12~ deficiency.
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